Monitor for upcoming Phase 1a topline results expected in Q4 2026 for TX2100, which could be a significant catalyst. The board leadership change is routine governance with no immediate financial implications.
Price Chart
Executive Summary
Tectonic Therapeutic appointed François Nader as Chair and independent director of the Board, replacing Terry McGuire who will step down as Chair in April 2026 and leave the Board after the 2026 Annual Meeting. The company also released a presentation on its HHT drug candidate TX2100, highlighting its preclinical success and ongoing Phase 1 trial, though no new clinical data was disclosed.
Key Facts
- François Nader appointed as Chair and independent director effective April 1, 2026
- Terry McGuire to step down as Chair in April 2026 and leave the Board after the 2026 Annual Meeting
- Nader will receive $70,000 annual cash compensation and an initial equity award of 20,400 stock options
- Company released presentation on TX2100 for Hereditary Hemorrhagic Telangiectasia (HHT)
- TX2100 Phase 1a trial ongoing with first subject randomized in February 2026
- No new clinical data or financial figures disclosed in the filing
Financial Impact
Minimal immediate financial impact. Director compensation includes $70,000 annual cash and initial equity grant of 20,400 options, but no material financial changes disclosed.
Risk Factors
- Clinical trial delays or adverse results for TX2100
- Dilution from future equity grants to directors and employees
- No approved therapies for HHT creates regulatory uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-066964 |
| Document: d50095d8k.htm | 0001193125-26-066964 |
| Document: d50095dex991.htm | 0001193125-26-066964 |
| Document: 0001193125-26-066964-index-headers.html | 0001193125-26-066964 |
| Document: 0001193125-26-066964-index.html | 0001193125-26-066964 |
| Document: 0001193125-26-066964.txt | 0001193125-26-066964 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | 144 | $36.47 | awaiting T+60 | — | $19.95 (−45.30%) |
Jun 11, 2026 19w ago | Institutional Cluster | $29.34 $30.75 | ▲ +4.81% | ▲ +0.41% | $19.95 (−32.00%) |
May 7, 2026 24w ago | 8-K | $29.00 $29.17 | ▼ −0.59% | ▲ +4.25% | $19.95 (+31.21%) |
May 7, 2026 24w ago | Press Release | $29.00 $29.17 | ▲ +0.59% | ▼ −4.25% | $19.95 (−31.21%) |
Apr 24, 2026 26w ago | DEFA14A | $28.75 $31.59 | ▲ +9.88% | ▲ +5.10% | $19.95 (−30.61%) |
Apr 3, 2026 29w ago | 3 | $29.98 $32.74 | ▲ +9.21% | ▼ −4.26% | $19.95 (−33.46%) |
Mar 6, 2026 33w ago | Insider Cluster | $35.87 $28.89 | ▼ −19.46% | ▼ −32.24% | $19.95 (−44.38%) |
Feb 24, 2026 34w ago | 8-K | $23.11 $28.84 | ▲ +24.79% | ▲ +17.84% | $19.95 (−13.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers